

REMARKS

Reconsideration of this application is respectfully requested. Applicants have canceled claims 29-31, 39, 40, and 45-49. Claims 50-55 are new and are derived from canceled claims 45-49. The amendment adds no new matter.

Substance of Interview

Applicants thank the Examiner for the Interview held on June 14, 2005. The outstanding rejections in this application were discussed. Applicants argued that adequate written description support for the pending claims could be found in the specification. The Examiner agreed that claims to an isolated/purified antibody that binds specifically to p12 or p18 would be allowable. **Accordingly, new claims 50-55 should be allowable.** The Examiner further agreed that that he would consider withdrawing the written description rejection of claims 29-31. The Examiner suggested canceling claims 39 and 40 to avoid potential double-patenting issues. The Examiner indicated that the utility rejection of claims 29-31 would be maintained.

Rejections under 35 U.S.C. §§ 101 and 112 for lacking utility

Claims 29-31 were rejected under 35 U.S.C. §§ 101 and 112 as allegedly not being supported by a well-established utility. Applicants traverse the rejection for the reasons set forth in applicants' May 18, 2004, Response. Nevertheless, solely to expedite allowance of this application, applicants have canceled claims 29-31. Thus, the rejection is moot.

Rejections under 35 U.S.C. § 112, first paragraph, for lacking an adequate written description

Claims 29-31, 39, 40, and 45-49 were rejected under 35 U.S.C. § 112, first paragraph, as allegedly containing subject matter that was not described in the

specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention.


Applicants traverse the rejection for the reasons set forth in applicants' May 18, 2004, Response. As pointed out by applicants during the interview with the Examiner, the pending claims are fully supported by the specification. Nevertheless, solely to expedite allowance of this application, applicants have canceled claims 29-31, 39, 40, and 45-49, and added new claims 50-55. Since the Examiner agreed that claims to an isolated/purified antibody that binds specifically to p12 or p18 would be allowable, **new claims 50-55 should be allowable.**

Applicants submit that this application is in condition for allowance, and respectfully request issuance of a Notice of Allowance. Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 26, 2005

By: 
Salvatore J. Arrigo
Reg. No. 46,063
Telephone: 202-408-4160
Facsimile: 202-408-4400
E-mail: arrigos@finnegan.com